Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E76.10 EPS (ttm)0.94 Insider Own0.10% Shs Outstand1.67B Perf Week0.03%
Market Cap118.88B Forward P/E22.04 EPS next Y3.23 Insider Trans-20.58% Shs Float1.67B Perf Month0.85%
Income1.57B PEG3.26 EPS next Q0.66 Inst Own74.40% Short Float1.18% Perf Quarter15.14%
Sales16.91B P/S7.03 EPS this Y-22.30% Inst Trans-0.03% Short Ratio3.28 Perf Half Y6.23%
Book/sh8.62 P/B8.26 EPS next Y25.95% ROA4.90% Target Price76.29 Perf Year8.01%
Cash/sh2.58 P/C27.60 EPS next 5Y23.35% ROE10.70% 52W Range50.91 - 73.06 Perf YTD4.16%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-2.50% Beta0.52
Dividend %2.13% Quick Ratio1.30 Sales past 5Y-3.20% Gross Margin76.00% 52W Low39.91% ATR1.28
Employees25000 Current Ratio1.50 Sales Q/Q8.70% Oper. Margin11.60% RSI (14)58.56 Volatility1.55% 1.87%
OptionableYes Debt/Eq0.47 EPS Q/Q0.50% Profit Margin9.30% Rel Volume0.65 Prev Close70.40
ShortableYes LT Debt/Eq0.46 EarningsApr 28 BMO Payout159.00% Avg Volume5.99M Price71.23
Recom2.30 SMA200.00% SMA505.05% SMA20010.84% Volume3,872,952 Change1.18%
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
May-25-16 02:00AM  Bloomsbury Publishing Plc :BMY-GB: Earnings Analysis: 2016 By the Numbers : May 25, 2016
May-24-16 05:50PM  Sartorius to expand pharmaceutical plant in Puerto Rico
06:27AM  [$$] Bristol-Myers Could Grow EPS 16% Per Year at
May-23-16 12:06PM  Don't Let Cancer Immunotherapy Hope Give Way To Hype at Forbes
11:15AM  Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights Business Wire
09:45AM  FDA staff question utility of Sanofi diabetes drugs Reuters
09:10AM  Coverage initiated on Bristol-Myers by Hilliard Lyons
08:49AM  FDA staff question dosing of Sanofi combination diabetes drug Reuters
05:00AM  A Rudderless Market
May-20-16 07:55AM  Looking for a Top Momentum Stock? 3 Reasons Why Bristol-Myers (BMY) is a Great Choice
May-19-16 12:03PM  Inovalon And Bristol-Myers Squibb Strike Deal To Focus On Real World Outcomes & Value-Based Contracting Initiatives
08:23AM  Bristol-Myers Reports Two-Year Overall Survival Opdivo Data
07:55AM  Inovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based Contracting Initiatives GlobeNewswire
May-18-16 06:07PM  New Hope for Melanoma Patients at MarketWatch
05:40PM  Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer Business Wire
05:00PM  Merck, Bristol drugs show longer survival for deadly cancers
11:03AM  The Highest-Earning Hedge Fund Manager in 2015 Reveals His Top Stock Picks for Q2 at Insider Monkey
09:26AM  Bristol-Myers' Opdivo Wins FDA Nod for Additional Indication
06:59AM  Breadth and Depth of Bristol-Myers Squibbs Immuno-Oncology Clinical Development Program to be Showcased at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
May-17-16 08:25PM  Bristol-Myers, AbbVie open two new facilities this week that will employ 250 at
07:04PM  Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA1 Business Wire
01:00PM  Bristol-Myers Squibb Opens Expanded Biologics Facility Business Wire
08:13AM  Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio Zacks
May-12-16 05:43PM  Bristol-Myers/AbbVie Empliciti Gets Approved in the EU
04:50PM  Exelixis, Inc. Prepares for Blastoff at Motley Fool
04:01PM  HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb GlobeNewswire
09:07AM  Behind Gilead Sciences Pricing Pressures for HCV Drugs in the US Market Realist
May-11-16 02:25PM  Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy Business Wire
11:31AM  European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibbs Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma Business Wire
09:07AM  Pfizers 1Q16 Earnings: Profitability and Financial Guidance Market Realist
08:01AM  Trending Now: BMY Yahoo Finance - Qwiki
May-10-16 12:18PM  1 Wonder Drug Sends Bristol-Myers Squibb Co. Rocketing 13% Higher in April at Motley Fool
May-09-16 10:47AM  [$$] Pfizer to trial triple-combination cancer treatment at Financial Times
09:32AM  These 5 Rocket Stocks Are Blasting Higher in May at TheStreet
May-06-16 04:44PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
12:05PM  How Do Eli Lillys Valuation Multiples Compare to Peers? Market Realist
08:16AM  Celldex (CLDX) Posts Wider Q1 Loss, Focus on Pipeline Zacks
May-05-16 05:13PM  Charts are bullish for health care: Technician Yahoo Finance
01:25PM  Merck beats 1Q profit views with tight cost controls AP
07:30AM  Modern Family Star Eric Stonestreet and His Mom, a Two Time Cancer Survivor, Join Forces to Raise Awareness of Immuno-Oncology Research through Ready. Raise. Rise. Campaign Business Wire
May-04-16 01:04PM  BRISTOL MYERS SQUIBB CO Financials EDGAR Online Financials
May-03-16 08:30PM  As Google's secretive biotech spinoff ramps up, look who it's hiring at American City Business Journals
May-02-16 05:28PM  3 stocks set to breakout? CNBC
09:20AM  Must-See Charts: How Healthy Are Bristol-Myers, Eli Lilly, Pfizer, Merck? at TheStreet
Apr-28-16 06:39PM  Cramer: Raging bull market brewing for pharma at CNBC
06:25PM  Cramer: Raging bull market brewing for pharma CNBC
03:20PM  Edited Transcript of BMY earnings conference call or presentation 28-Apr-16 2:30pm GMT Thomson Reuters StreetEvents
01:25PM  Bristol-Myers (BMY) Stock Climbs on Q1 Earnings, Revenue Beat at TheStreet
01:17PM  Bristol raises 2016 forecast after earnings beat Reuters
01:07PM  Bristol-Myers Hits 17-Year High On Q1 Report; Celgene Also Up at Investor's Business Daily
12:48PM  Today's buzz on the NYSE trading floor was clearly: "take 'em" Yahoo Finance
11:58AM  Heres Why Investors Are Watching These Five Stocks Today at Insider Monkey
11:27AM  Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View Zacks
11:22AM  Facebook hits new high; DreamWorks' $3.8 billion deal; Amazon results on tap Yahoo Finance
09:20AM  Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance at 24/7 Wall St.
09:08AM  How Bristol-Myers Squibb (BMY) Stock Stands Out in a Strong Industry Zacks
08:27AM  Bristol-Myers (BMY) Beats on Q1 Earnings and Revenues Zacks
08:18AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
07:21AM  Bristol-Myers tops Street 1Q forecasts AP
07:07AM  Q1 2016 Bristol-Myers Squibb Co Earnings Release - Before Market Open CCBN
07:03AM  Bristol-Myers Profit Beats Expectations, 2016 Guidance Raised at Bloomberg
07:00AM  Bristol-Myers 1Q sales jump but costs keep its profit flat AP
06:59AM  Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire
06:59AM  Bristol raises 2016 forecast after first-quarter earnings beat Reuters
06:59AM  [$$] Bristol-Myers Revenue Rises 8.7%, at The Wall Street Journal
Apr-27-16 12:52PM  How Will Bristol-Myers (BMY) Stock React to Tomorrow's Q1 Earnings? at TheStreet
10:00AM  Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference Business Wire
Apr-26-16 03:21PM  3 Stocks Any Investor Can Buy at Motley Fool
03:00PM  Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin! at Motley Fool
08:00AM  New ranking crowns JPMorgan the top US company for diversity and inclusion at CNBC
07:27AM  [$$] Allied Minds Supports Bristol-Myers Partnership With $80M Fund at The Wall Street Journal
Apr-25-16 12:57PM  Busiest earnings week of the quarter CNBC
07:10AM  Goldman Sach's 5 Large-Cap Pharma Stock Favorites Ahead of Earnings at TheStreet
07:08AM  Big Drug Stocks to Report This Week: LLY, GSK, VRTX, BMY, ABBV Zacks
06:59AM  Bristol-Myers Squibbs Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Business Wire
Apr-22-16 12:31PM  Bristol-Myers (BMY) Q1 Earnings: Can the Stock Surprise? Zacks
Apr-21-16 12:41PM  3 Dividend Stocks for Retirees at Motley Fool
09:59AM  Moving Average Crossover Alert: Bristol-Myers (BMY) Zacks
09:00AM  How These Drug Manufacturers BMY, LLY, AZN, and GSK are Performing Accesswire
Apr-20-16 06:05PM  Is Sanofi Trying to Acquire Medivation? Market Realist
Apr-19-16 01:22PM  [$$] Roche 'very optimistic' on prospects for new cancer drugs at Financial Times
09:30AM  Bristol-Myers' Opdivo extends survival in head and neck cancer -study Reuters
09:30AM  First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigators Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Business Wire
09:30AM  Bristol-Myers's Opdivo Extends Survival in Head, Neck Cancer at Bloomberg
Apr-18-16 03:00PM  Drug giant plots Peninsula expansion, 150 more jobs at
09:41AM  5 Stocks to Supplement Your Social Security Benefits at Motley Fool
Apr-17-16 03:15PM  First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma Business Wire
Apr-16-16 11:41AM  The Big Downside to Better Medicine? Higher Prices at Motley Fool
Apr-15-16 01:25PM  Lessons for Theranos: Patients matter more than disruption at
11:22AM  [$$] Best Bets in Biopharma at
08:49AM  EU extends safety review of chronic Hep C treatments Reuters
05:57AM  Low Expectations Could Yield Positive Surprises
Apr-14-16 05:45PM  New tests for choosing right hep C drug could save money
04:30PM  Stand Up To Cancer launches new industry-supported research program at
08:49AM  [$$] FDA to Review Bristol-Myers's Opdivo for Hodgkin Lymphoma at The Wall Street Journal
06:59AM  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Supplemental Biologics License Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients Business Wire
05:19AM  [$$] China to punish officials in vaccine scandal at Financial Times
Apr-13-16 04:57PM  What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today at Motley Fool
03:53PM  [$$] A Perfect Climate for Bond-Like Stocks at
03:39PM  3 Biotech Takeover Targets That Could Get Bought Soon at Motley Fool
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM
ANDREOTTI LAMBERTODirectorOct 06Sale59.7311,600692,904524,252Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorOct 05Sale61.9911,600719,027535,852Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorSep 03Sale59.5711,600691,032546,874Sep 03 06:34 PM
ANDREOTTI LAMBERTODirectorSep 02Sale59.2211,600687,005558,474Sep 03 06:34 PM
Blin EmmanuelSVP, Head of CommercializationJul 02Option Exercise0.009510953Jul 07 05:13 PM
Gordon MurdoSVP, Head of Worldwide MarketsJul 01Option Exercise0.002,33502,540Jul 06 07:17 PM
Caldarella Joseph CSVP & ControllerJun 04Sale65.7116,9721,115,22959,284Jun 08 04:17 PM